


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Application Number</b>	09/891,023
				<b>Filing Date</b>	06-25-01
				<b>First Named Inventor</b>	Janigro
				<b>Group Art Unit</b>	1645 1647
				<b>Examiner Name</b>	Unknown Nichols
Sheet	1	of	2	Attorney Docket Number	26336-8

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
GG	AA	6,268,223	B1	Cornell-Bell et al.	07/31/2001	_____
GG	AB	6,117,989		Bandman et al.	09/12/2000	_____
GG	AC	5,866,347		Swedo et al.	02/02/1999	_____
GG	AD	5,304,367		Biegon	04/19/1994	_____
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

Examiner Signature		Date Considered	1/30/03
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office. U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

### Complete if Known

Application Number	09/891,023
Filing Date	06-25-01
First Named Inventor	Janigro
Group Art Unit	1643 1647
Examiner Name	Unknown Nichols

TECH

REC

JAN

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CSA	BA	Tumor Markers in Peripheral Blood of Patients with Malignant Melanoma: Multimarker RT-PCR Versus a Luminoimmunometric Assay for S-100; Berking, Carola et al.; Arch Dermatol Res (1999) 291: 479-484.	2001
CSA	BB	Evaluation of Serum Markers of Neuronal Damage Following Severe Hypoglycaemia in Adults with Insulin-Treated Diabetes Mellitus; Strachan, Mark, W., et al.; Diabetes/Metabolism Research & Reviews 1999; 15: 5-12.	1
CSA	BC	Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means; Kroll, Robert A. & Neuweit, Edward A.; Neurosurgery, Vol. 42, No. 5; May 1998.	1
CSA	BD	Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis; Terryberry, J.W. et al.; Neurobiology of Aging, Vol. 19, No. 3, pp. 205-216, 1998.	1
CSA	BE	Cerebrospinal Fluid Analysis Differentiates Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis; Jongen, Peter J. H. et al., Neurol Neurosurg Psychiatry 1997; 63:446-451.	1
CSA	BF	S-100 Release in Hypothermic Circulatory Arrest and Coronary Artery Surgery; Wong, Carl H. et al.; Ann Thorac Surg 1999; 67:1911-4.	1
CSA	BG	Serum S100 Protein: A Potential Marker for Cerebral Events During Cardiopulmonary Bypass; Westbay, Stephen et al.; Ann Thorac Surg 1996; 61:88-92.	1
CSA	BH	Serum anti-GFAP ad anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia; Mecocci, P. et al.; Journal of Neuroimmunology 57 (1995) 165-170.	1
CSA	BI	Uncontrolled Reoxygenation by Initiating Cardiopulmonary bypass is Associated with Higher Protein S100 in Cyanotic Versus Acyanotic Patients; Mathews, G. et al.; Thorac Cardiov Surg 2000; 48: 263-268.	1
	BJ		
	BK		

Examiner Signature

Date Considered

11/20/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.